Drug Trial Radar · NCT06091254
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
822
Planned (sponsor's estimate)
Start
Dec 12, 2023
Primary completion
Feb 29, 2028
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone. The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the "comparator drug") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects quality of life and ability to complete routine daily activities.
Conditions
- Follicular Lymphoma (FL)
Interventions
OdronextamabDrug
Administered per the protocol
RituximabDrug
Administered per the protocol
CyclophosphamideDrug
Administered per the protocol as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy
DoxorubicinDrug
Administered per the protocol as part of CHOP chemotherapy
VincristineDrug
Administered per the protocol as part of CHOP, and CVP chemotherapy
Prednisone/prednisoloneDrug
Administered per the protocol as part of CVP chemotherapy
BendamustineDrug
Administered per the protocol as part of chemotherapy (Rituximab-Bendamustine)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs) for odronextamabTime frame: Up to 35 days
- Incidence of Treatment-Emergent Adverse Events (TEAEs) of odronextamabTime frame: Up to 2 years
- Severity of TEAEs of odronextamabTime frame: Up to 2 years
- Complete Response at 30 months (CR30) as assessed by independent central reviewTime frame: Up to 30 months
Locations
190 sites in 19 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center
Tucson, Arizona · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
UC Irvine Health
Orange, California · Withdrawn
Investigative Clinical Research of Indiana
Noblesville, Indiana · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi · Completed
Icahn School of Medicine at Mt Sinai
New York, New York · Recruiting
Stony Brook University Hospital
Stony Brook, New York · Recruiting
Clinical Research Alliance Inc
Westbury, New York · Withdrawn
University of North Carolina
Chapel Hill, North Carolina · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Center for Oncology and Blood Disorders
Houston, Texas · Recruiting
HOPE Cancer Center of East Texas
Tyler, Texas · Withdrawn
Huntsman Cancer Institute - Oncology Division
Salt Lake City, Utah · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Withdrawn
Prohealth Care Inc
Waukesha, Wisconsin · Withdrawn
Ingham Institute
Liverpool, New South Wales, Australia · Recruiting
Icon Cancer Centre - Wesley
Auchenflower, Queensland, Australia · Completed
Flinders Medical Centre
Bedford Park, South Australia, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Epworth Freemasons
East Melbourne, Victoria, Australia · Recruiting
Alfred Hospital and Monash University
Melbourne, Victoria, Australia · Recruiting
St Vincents Hospital Melbourne
Melbourne, Victoria, Australia · Recruiting
Ordensklinikum Linz Gmbh, Elisabethinen
Linz, Austria · Recruiting
Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III
Salzburg, Austria · Recruiting
Medical University of Vienna
Vienna, Austria · Recruiting
Hanusch Krankenhaus
Vienna, Austria · Recruiting
Ordensklinikum Linz
Linz, Osterreich, Austria · Recruiting
Ziekenhuis Netwerk Antwerpen Stuivenberg
Antwerp, Belgium · Withdrawn
Institut Jules Bordet
Brussels, Belgium · Withdrawn
AZ St.-Elisabeth Herentals vzw
Herentals, Antwerp, Belgium · Withdrawn
Hopital De Jolimont
La Louvière, Hainaut, Belgium · Withdrawn
Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium · Withdrawn
Instituto DOr de Pesquisa e Ensino Df Star
Brasília, Brazil · Recruiting
Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro, Brazil · Withdrawn
Instituto Americas
Rio de Janeiro, Brazil · Recruiting
Showing 40 of 190 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.